



ceocfointerviews.com
All rights reserved!
Issue: November 20, 2017



CEOCFO Magazine

Q&A with Patrick Antaki, Co-Founder and CEO of Evergaze LLC bringing to market Advanced Digital Eyewear combining Prescription Glasses and a Lightweight Device enabling Macular Degeneration and Diabetic Retinopathy patients to Compensate for Vision Loss and Lead More Active Lives



Patrick Antaki
Co-Founder & Chief Executive Officer

Evergaze LLC
www.seeboost.com

Contact:
Patrick Antaki
(972) 896-4937
pantaki@evergaze.com

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFO Magazine

“seeBOOST is a practical alternative to going blind from macular degeneration or diabetes.”- Patrick Antaki

CEOCFO: *Mr. Antaki, what is the idea behind Evergaze and seeBOOST?*

Mr. Antaki: The concept is very simple: to provide prescription eyeglasses to a person suffering from macular degeneration or from diabetic retinopathy. No such thing has been done before. Ours is the first of its kind, the first concept and product that works so that when you lose vision due to these diseases you can in fact wear glasses to compensate for your vision loss.

CEOCFO: *Would you tell us a little bit about macular degeneration?*

Mr. Antaki: Macular degeneration is usually referred to as age-related macular degeneration, because it impacts persons who are older. It can start as early as your fifties. More than a third of persons in their eighties have it to varying degrees. The way you know it is when you lose central vision. In other words, the portion of your vision that is directly in front of you where you are gazing, such as when reading, watching television or looking at faces, is no longer working. While you lose that portion of your vision, your peripheral vision remains unaffected. Even though the loss of vision is in a tiny circle in the center, it is very debilitating because that is where all of the detailed resolution in the eye is located. Therefore, these diseases have a significant impact on what you can and cannot do. There is no cure or treatment. The primary risk factor is simply growing old. There is a similar effect with diabetic retinopathy, whereby you also lose vision but as a result of diabetes. It is a very similar result in terms of loss of vision as with macular degeneration, even though diabetes is an entirely different disease vector. The number of persons suffering from both diseases is growing in almost direct proportion to the aging population around the world.

CEOCFO: *What have you developed at Evergaze?*

Mr. Antaki: We have developed eyeglasses that you can wear as comfortably as regular prescription eyeglasses. On these glasses we added a very sophisticated electro-optical system. Essentially, you are looking into a miniature television screen, although the image appears very large to you. That image is digitally enhanced so that what is physically in front of you is visually compensated for the vision loss, making easier to perceive. Crucially, seeBOOST, the name of our product, is ultra lightweight and extremely comfortable.

CEOCFO: *Is it one size fits all?*

Mr. Antaki: We mount the device onto conventional prescription glasses. Therefore, the prescription glasses themselves are customized for each person in that the frame size and type can be unique, just like any prescription glasses would be,